Perioperative Apalutamide Shows Reduced Metastasis and Death Risk in High-Risk Prostate Cancer

A substudy of the international Phase 3 PROTEUS clinical trial, presented at the European Society for Medical Oncology (ESMO) Congress 2026 and published in European Urology, provides further evidence that perioperative apalutamide combined with hormone therapy before and after prostate cancer surgery reduces the risk of metastasis or death in patients with high-risk localized or locally advanced prostate cancer. This regimen demonstrated superior efficacy compared to standard radical prostatectomy alone.